The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.

By staying up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy, the clinicians will be able to provide appropriate care using a shared decision-making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.

Clinicians need to know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical; over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.

With expanding treatment options, clinicians are challenged to understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Staying up-to-date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.